文献速递细菌感染、耐药与抗菌药物

米诺环素联合利福平治疗MRSA所致复杂性皮肤和皮肤结构感染患者的人群药代动力学/药效学研究

Population pharmacokinetics/pharmacodynamics of minocycline plus rifampicin in patients with complicated skin and skin structure infections caused by MRSA.
PubMed 文献 · J Antimicrob Chemother · 2024-01-01

本研究在口服米诺环素联合利福平对比利奈唑胺的4期研究患者中构建三种药物的人群PK模型,三室模型拟合良好,PK/PD指标与临床结局无关;按米诺环素fAUC24h/MIC>0.5的目标,96%(49/51)患者达标。

要点

  • 米诺环素、利福平和利奈唑胺的人群PK均以三室模型(含吸收室)最佳描述。
  • 按米诺环素联合利福平时fAUC24h/MIC>0.5的目标,96%(49/51)患者达标。
  • PK/PD指标与临床结局无关,AUC、MIC及AUC/MIC比值均未能与结局关联。

核心结论

  • 建立了MRSA复杂性皮肤和软组织感染患者中米诺环素、利福平和利奈唑胺的人群PK模型,几乎所有患者达到预设药效学指标目标,因此AUC、MIC及AUC/MIC比值均未能与临床结局关联。

研究设计与样本

  • 样本来自一项口服米诺环素联合利福平对比利奈唑胺的4期研究,该研究显示米诺环素联合利福平非劣于利奈唑胺。
  • 抗生素采用HPLC或LC-MS测定,使用Pmetrics构建人群PK模型,并探索PK/PD指标与患者结局的关联。

主要发现

  • 含吸收室、一级输入和消除的三室模型最佳描述三种药物的数据,最终模型未纳入协变量。
  • 清除率和分布容积的人群中位值(95%可信限):米诺环素7.412 L/h(5.121-8.361)和14.155 L(6.799-33.901),利福平5.683 L/h(3.703-7.726)和7.736 L(6.031-8.948),利奈唑胺1.970 L/h(1.326-2.499)和20.169 L(12.857-32.629)。
  • 最大后验概率贝叶斯估计的观测值对预测值斜率:米诺环素0.999(r²=0.967),利福平0.998(r²=0.769),利奈唑胺0.998(r²=0.895)。
  • PK/PD指标与临床结局无关;按米诺环素联合利福平时fAUC24h/MIC>0.5的目标,96%(49/51)患者达到目标。

关键数值与推荐

  • 米诺环素联合利福平时采用的转化性fAUC24h/MIC目标为>0.5,96%(49/51)患者达到该目标。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The population pharmacokinetics/pharmacodynamics (PK/PD) of minocycline, rifampicin and linezolid in patients with complicated skin and soft tissue infections (cSSTIs) caused by MRSA are described. METHODS: Samples were collected in a Phase 4 study of oral minocycline plus rifampicin versus linezolid showing minocycline plus rifampicin to be non-inferior to linezolid. Antibiotics were assayed by HPLC or LC-MS, and a population PK model was developed using Pmetrics. The association between PK/PD indices and patient outcomes was explored. RESULTS: A three-compartment model (with an absorption compartment) with first-order input and elimination best described the data for the three drugs. No covariates were included in the final model. The population median values (95% credibility limits) of the clearance and volume of distribution were 7.412 L/h (5.121-8.361) and 14.155 L (6.799-33.901) for minocycline, 5.683 L/h (3.703-7.726) and 7.736 L (6.031-8.948) for rifampicin, and 1.970 L/h (1.326-2.499) and 20.169 L (12.857-32.629) for linezolid, respectively. Maximum a posteriori probability-Bayesian estimation plots of observed versus predicted had a slope of 0.999 r20.967 for minocycline, slope 0.998 r20.769 for rifampicin and slope 0.998 r20.895 for linezolid. PK/PD indices were not related to clinical outcome. Taking a translational minocycline fAUC24h/MIC target of >0.5 for minocycline in the presence of rifampicin, 96% (49/51) of patients reached the target. CONCLUSIONS: Population PK models of minocycline, rifampicin and linezolid were developed in patients with MRSA cSSTI and almost all patients reached the predefined PD index targets. As a result, neither AUC, MIC nor the AUC/MIC ratio could be related to clinical outcome.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Pardos SL, Hope W, Kotsaki A, et al. Population pharmacokinetics/pharmacodynamics of minocycline plus rifampicin in patients with complicated skin and skin structure infections caused by MRSA. J Antimicrob Chemother. 2024. PMID: 39412246. doi:10.1093/jac/dkae363

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。